Antioxidant effect of Legalon® SIL in ischemia-reperfusion injury of rat skeletal muscle

Yusuf Ergün1, Muhammed Üremiş11, Metin Kılınç111, Tuğrul Ahtı1

DOI: http://dx.doi.org/10.1590/S0102-865020160040000007

1Professor, Department of Pharmacology, School of Medicine, Kahramanmaraş Sütçü İmam University, Turkey. Conception, design, intellectual and scientific content of the study; acquisition, analysis and interpretation of data; technical procedures; statistics analysis; manuscript preparation and writing; critical revision; final approval.

II Msc, Department of Biochemistry, School of Medicine, Kahramanmaraş Sütçü İmam University, Turkey. Acquisition of data, technical procedures, final approval.

III Professor, Department of Biochemistry, School of Medicine, Kahramanmaraş Sütçü İmam University, Turkey. Acquisition of data, technical procedures, final approval.

IV Assistant Professor, Department of Traumatology & Orthopedics, Üsküdar State Hospital, Istanbul, Turkey. Statistics analysis, manuscript writing, critical revision, final approval.

ABSTRACT

PURPOSE: To evaluated the potential antioxidant agent Legalon® SIL (silibinin-C-2’,3-bis(hydrogensuccinat)) in the skeletal muscle of rats.

METHODS: IRI was achieved via tourniquet application in Wistar-albino rats. Experimental groups were chosen as (i) sham control, (ii) IRI (3+2 h), (iii) IRI and Legalon® SIL-50 (50 mg/kg/i.p.), (iv) IRI and Legalon® SIL-100 (100 mg/kg/i.p.), and (v) IRI and Legalon® SIL-200 (200 mg/kg/i.p.). Muscle viability (evaluated by triphenyltetrazolium chloride dye method), malondialdehyde, superoxide dismutase, catalase, and glutathione peroxidase were assessed in muscle samples using a spectrophotometer.

RESULTS: Although viability of the injured limb non-significantly declined in the IRI group, administration of Legalon® SIL did not prevent injury. However, dramatic increase observed in malondialdehyde levels in the IRI group was prohibited by Legalon® SIL in a statistically significant manner. In comparison with the sham-control group, IRI and Legalon® SIL administration did not cause any significant alterations in the levels of superoxide dismutase, catalase, and glutathione peroxidase.

CONCLUSION: Although Legalon® SIL was not sufficient to prevent muscle injury in terms of viability, it is found to be an effective option to reduce reactive oxygen species-induced cell injury.

Key words: Ischemia. Reperfusion Injury. Oxidative Stress. Muscle, Skeletal. Rats.
Introduction

Ischemia-reperfusion injury (IRI) of skeletal muscle appears in various types of clinical conditions such as thrombolytic therapy, aortic cross-clamping during repair of abdominal aortic aneurysms, replantation, free tissue transfer, composite tissue allotransplantation, time-consuming reconstructive operations, tourniquet application, and crush injury. Among several mechanisms suggested to be responsible for IRI, reactive oxygen species (ROS)-induced cell injury has been indicated to have a prominent role in the etiology of this type of injury. In harmony, ROS generation in response to reperfusion of ischemic skeletal muscle has been shown to account for the etiology of IRI. In this context, a rational approach has been the use of agents with antioxidant potential in order to protect the tissue from oxidative stress-induced damage. Several antioxidant substances, thus, have been used to mitigate the injury, though with no established clinical benefit to date. For this reason, there is still a need to discover novel molecules to be used in IRI.

Silymarin, an extract of Silybum marianum (milk thistle), has been applied in order to alleviate suffering from various liver diseases. Constituting approximately 50% of silymarin, silibinin has been shown to have anti-oxidant and anti-inflammatory properties. Indeed, silymarin and silibinin have been found to exert beneficial effects in various IRI models established in different tissues, including the liver, the brain, the kidneys, the heart, and the intestine. As there had been no prior investigations exploring the potential effect of silibinin on IRI of skeletal muscle, we previously made an attempt to investigate its effects in a rodent model. Since silibinin is not water-soluble, we used ethanol to dissolve the substance. Unexpectedly, however, ethanol, as a vehicle, showed protective effects on IRI, thereby preventing a proper testing of the effects of silibinin due to masking. For this reason, we, in the present study, selected a water soluble form of silibinin, Legalon® SIL (silibinin-C-2’,3-bis (hydrogensuccinat)), to properly explore the exact effect in a tourniquet-induced IRI rat model.

Methods

The experiments were conducted in adherence with the European Communities Council Directive (86/609/EEC) and the Council for International Organization of Medical Sciences-CIOMS. It was approved by the Kahramanmaraş Sütçü İmam University Animal Ethics Committee (2012/5-4).

Animal preparation and IRI model

Adult male Wistar-albino rats were kept in a room with a temperature of 22±2°C and a humidity of 50-60% in a 12 h day/night cycle, and fed with laboratory chow and water ad libitum. Intraperitoneal urethane (1000 mg/kg/IP, Sigma-Aldrich) was administered before the experiment to attain general anesthesia throughout the procedure. Ischaemia was achieved by the application of an elastic rubber band as high as possible around the right thigh of the rat, and ischaemic period was selected to be 3 h. After the rats had been fixed on a pad, a 60 W household light bulb was placed above the animals and powered on in order to keep body temperatures constant at 36±1°C, measured using a rectal thermometer. Heads of the rats were shielded by aluminum foil to avoid overheating and dehydration. After the tourniquet had been released, the limb was allowed to perfuse for 2 h. Ischaemia and reperfusion of the limbs were confirmed by observation of changes in the color of the paws. At the end of the perfusion period, muscle samples were collected directly from right and left gastrocnemius muscles in succession. The animals were then killed by cervical dislocation under general anesthesia.

Experimental protocols

The rats were randomly allocated to one of the five groups (n=6): sham control group, where rats solely received urethane anesthesia (Group I), IRI group, where rats were subject to tourniquet-based IRI (Group II), and Legalon® SIL-50, Legalon® SIL-100, Legalon® SIL-200 groups, where rats received Legalon® SIL (50, 100, and 200 mg/kg/i.p., respectively) in addition to IRI (Group III, IV, V). Legalon® SIL (Madaus GmbH, Cologne, Germany (Rottapharm/Madaus Group)) was dissolved in saline (12.5 ml/kg) and administered 30 min prior to the reperfusion period. The doses were selected according to the literature.

Tissue viability for gastrocnemius muscle by the triphenyltetrazolium chloride method

At the end of the ischaemia-reperfusion period, gastrocnemius muscles were excised from both sides of the hind limbs and were rinsed in ice-cold Ringer’s lactate solution. Muscle samples were dissected free of blood vessels, nerves, and fascia. The samples were stored at -80°C until the assessment day. Viability was then evaluated by the triphenyltetrazolium chloride method, which assesses mitochondrial oxidative enzyme activity and is an indicator of irreversible cellular infarction.
Briefly, gastrocnemius muscles were weighed and homogenized in 3 ml of 0.25 M sucrose. Additional sucrose was then added to make a 20 percent homogenate by weight. The homogenate was filtered through a fine stainless steel mesh to remove any remaining fragments of fascia. Protein content of the homogenate was determined by the method of Lowry et al. A 1 ml aliquot of the homogenate was then mixed with 1 ml of 0.15 percent triphenyltetrazolium chloride (Sigma, St.Louis, MO) in 0.033 M phosphate buffer (dibasic sodium phosphate, pH 7.4). Reactions were performed in triplicate. The reaction mixture was stirred on a vortex mixer and incubated at 39°C in a shaking water bath for 1 h. After the reaction had been stopped, the mixture was diluted with 4 ml of acetone, centrifuged for 10 min at 1,500 rpm, and absorbance of clear red formazan dye was measured at 485 nm in a spectrophotometer (Shimadzu, Japan). Absorbance per mg protein was calculated for each limb, and the activity of each ischaemic limb was compared with the contralateral control limb to express the ischaemic limb activity as a percentage of that of the control limb.

**Biochemical measurements**

Tissues were weighed, blotted on filter paper, and homogenized with three volumes of ice-cold 1.15% KCl. The activities of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX), and the level of malondialdehyde (MDA) were measured in the supernatants obtained from centrifugation at 14,000 rpm.

MDA levels, reflecting lipid peroxidation rate in tissue samples, were measured according to procedure of Ohkawa et al. The reaction mixture contained 0.1 ml tissue sample, 0.2 ml of 8.1% sodium dodecyl sulphate (SDS), 1.5 ml of 20% acetic acid, and 1.5 ml of 0.8% aqueous solution of TBA. The pH of the mixture was then adjusted to 3.5, the volume was made up to 4.0 ml with distilled water, and a 5.0 ml mixture of n-butanol and pyridine (15:1,v/v) was added. The mixture was shaken vigorously. After centrifugation at 4,000 rpm for 10 minutes, the absorbance of the organic layer was measured at 532 nm. The protein concentration of tissue samples was measured by a Spectronic-UV 120 spectrophotometer using the method of Lowry et al. MDA levels in tissue samples were expressed as nmol/mg protein.

SOD activity was measured according to the method described by Fridovich. This method employs xanthine and xanthine oxidase to generate superoxide radicals which react with p-iodonitrotetrazlum violet (INT) to form a red formazan dye, which was measured at 505 nm. Assay medium consisted of the 0.01 M phosphate buffer, 3-cyclohexilamino-1-propanesulfonic acid (CAPS) buffer solution (50 mM CAPS, 0.94 mM EDTA, saturated NaOH) with pH 10.2, solution of substrate (0.05 mM xanthine, 0.025 mM INT), and 80 µL xanthine oxidase. SOD activity in tissue samples was expressed as U/mg protein.

CAT activities were determined by measuring the decrease in hydrogen peroxide concentration at 230 nm using the method of Beutler. Assay medium consisted of 1 M Tris HCl, 5 mM Na_,EDTA_ buffer solution (pH 8.0), ) 1 M phosphate buffer solution (pH 7.0), and 10 mM H_2O_2. CAT activities in tissue samples were expressed as U/mg protein.

GPX in tissue samples was assayed in a 1-ml system containing potassium phosphate buffer (0.1 M, pH 7.0), NADPH (0.2 mM), glutathione reductase (1 i.u), GSH (4 mM), EDTA (4 mM), sodium azide (4 mM), and appropriate amount of enzyme glutathione peroxidase (0.02 ml). The reaction mixture was incubated at 37°C for 10 minutes after 10 µL of 10 mM had been added to start the reaction. No r-butyl hydroperoxide was added to the blank cuvette. The rate of reaction was measured at 37°C by following the decrease in absorbance at 340 nm using a spectrophotometer. Activity in tissue samples was expressed in units per milligram of protein.

**Statistics**

Data were expressed as means±SEM. When normal distribution and homogeneity of variances were lacking in groups, non-parametric tests, i.e., Kruskal-Wallis test and Mann-Whitney U test, were performed. However, data were, generally, analyzed by one way analysis of variance (ANOVA), with the significance of individual comparisons assessed by Bonferroni test. P values less than 0.05 were accepted as significant.

**Results**

*The effect of Legalon*®* SIL on tissue viability in skeletal muscle*

The principle of triphenyltetrazolium chloride method in exploring IRI is that viable mitochondrial enzymes of the redox cytochrome chain convert a tetrazolium compound to a coloured dye, formazan. Formation of this dye is thus used to measure mitochondrial oxidase enzyme activity which reflects the viability of muscle cells. The viability of the ischaemic-reperfused limb, reported as a percentage of the value obtained for the normal
Antioxidant effect of Legalon® SIL in ischemia-reperfusion injury of rat skeletal muscle

Contralateral muscle, can be used for an accurate comparison among experimental groups. In the present study, as the Shapiro-Wilk test of normality had indicated normal distribution of data regarding all groups (P=0.664, P=0.963, P=0.723, P=0.376, P=0.606 for Groups I through V, respectively) and the test of homogeneity of variances had showed a P value above 0.05 (P=0.190), statistics were calculated using parametric tests. Statistical analysis with respect to all groups indicated no difference (ANOVA, F=2.342, P=0.088). However, viabilities of ischemic limbs were 74±10% and 55±7% in sham control and IRI groups, respectively (Figure 1). Although statistically not significant, a decline in viability was seen in the latter (Figure 1). Furthermore, Legalon® SIL was not able to prevent this decline caused by IRI, since values obtained from Legalon® SIL-50, Legalon® SIL-100, and Legalon® SIL-200 groups were similar to that from the IRI group (Figure 1).

\[ \text{Viability} = \frac{\text{Contralateral muscle}}{\text{Infarcted muscle}} \times 100 \]

**FIGURE 1 - Viability of ischemic hindlimb as a percentage of the contralateral control muscle.** Group I: sham control, Group II: IRI (3+2 h), group III: IRI and Legalon® SIL-50 (50 mg/kg/IP), group IV: IRI and Legalon® SIL-100 (100 mg/kg/IP), group V: IRI and Legalon® SIL-200 (200 mg/kg/IP) (n=6 per group). Data were expressed as means±SEM and one way analysis variance (ANOVA) with Bonferroni test was performed, significance was accepted P<0.05, * vs. group I.

<table>
<thead>
<tr>
<th>Groups</th>
<th>MDA</th>
<th>SOD</th>
<th>CAT</th>
<th>GPX</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>0.50±0.17</td>
<td>0.24±0.04</td>
<td>3.36±0.23</td>
<td>0.45±0.08</td>
</tr>
<tr>
<td>II</td>
<td>2.24±0.77*</td>
<td>0.36±0.04</td>
<td>3.07±0.36</td>
<td>0.44±0.03</td>
</tr>
<tr>
<td>III</td>
<td>0.34±0.10**</td>
<td>0.19±0.05</td>
<td>2.36±0.26</td>
<td>0.35±0.04</td>
</tr>
<tr>
<td>IV</td>
<td>0.59±0.30**</td>
<td>0.37±0.09</td>
<td>3.38±0.32</td>
<td>0.42±0.04</td>
</tr>
<tr>
<td>V</td>
<td>0.26±0.17**</td>
<td>0.34±0.03</td>
<td>2.90±0.14</td>
<td>0.39±0.03</td>
</tr>
</tbody>
</table>

**TABLE 1 - MDA, SOD, CAT, and GPX levels of the muscle.**

Discussion

The present study showed that Legalon® SIL was insufficient in preventing cellular infarction, which was assessed by triphenyltetrazolium chloride method. However, it was found to have the capacity to prevent ROS-induced lipid peroxidation in a skeletal muscle IRI model of rat.

Although a statistically significant difference could not be detected between the sham control and IRI groups, tissue viability of the latter (54±7%) seemed to be less than that of the former (74±10%). This may suggest that ischaemia-reperfusion insult brings about a slight but considerable degree of cellular infarction in skeletal muscle of rats. However, none of the doses of Legalon® SIL were able to prevent cellular infarction. Although not statistically significant, 200 mg/kg dose of the drug was observed to indeed worsen the injury (34±4%). This may imply that Legalon® SIL, particularly at the highest dose, may facilitate...
cellular infarction in the current experimental setup. In fact, in a previous study performed in our laboratory, administration of 200 mg/kg silibinin had not been tolerated by the mice (i.e. almost all died probably due to lung edema), and the dose was reduced to an effective but not harmful level (50 mg/kg)\(^9\). Nevertheless, the probability of the highest dose of Legalon® SIL being toxic is less than it simply being ineffective against cellular infarction in the present study. According to the Preclinical Safety Data of the manufacturer, the drug has proved to be virtually non-toxic and the LD\(_{50}\) levels after intravenous injection had been classified as >1000 mg/kg in both male and female rats and mice. These results are in harmony with the toxicity profile of silymarin, for which LD\(_{50}\) regarding acute toxicity after intravenous infusion has been detected to be 385 mg/kg in rats\(^{26}\). In our previous study in mice, ethanol, the compound used to solve silibinin, may have contributed to the toxicity observed. Finally, as a medicinal product registered for mushroom poisoning in Germany, Legalon® SIL comprises chemicals other than silibinin, such that 528.5 mg silibinine-C-2',3-bis(hydrogensuccinate) disodium salt is equivalent to 350 mg silibinin, rendering active constituent exposure of rats to less than 200 mg/kg.

In the present study MDA, a marker of ROS-induced lipid peroxidation, increased in a statistically significant manner in IRI group in comparison with the sham control group. In contrast to peroxidation, increased in a statistically significant manner in IRI 200 mg/kg. Silibinin, rendering active constituent exposure of rats to less than 2',3-bis(hydrogensuccinate) disodium salt is equivalent to 350 mg chemicals other than silibinin, such that 528.5 mg silibinine-C-2',3-bis(hydrogensuccinate) disodium salt is equivalent to 350 mg silibinin, rendering active constituent exposure of rats to less than 200 mg/kg.

As an antioxidant agent, Legalon® SIL is the antioxidant effect of silymarin/silibinin derived from studies conducted in tissues other than skeletal muscle are as follows: (i) scavenging ROS, (ii) increasing the content of glutathione, (iii) stimulation of the expression of SOD, (iv) prevention of the effects of tumour necrosis factor-α (TNF-α), which markedly increases lipid peroxidation, (v) inhibition of neutrophil migration, and (vi) inhibition of CYP450, some of which generate ROS\(^{20}\). In one study, silymarin has been shown to reduce the levels of TNF-α in parallel with those of heat shock protein (HSP)-70, SOD, and thiobarbituric acid-reactive substance (TBARS) in a rat model of mesenteric IRI model, indicating the role of TNF-α in the potential compensation mechanisms resulting from up-regulation of relevant genes to prevent a decrease in enzyme activity can be another rational explanation. The main factor specifying the direction of enzyme activity may be the amount of ROS produced. Perhaps above a critical level of ROS concentration, the first scenario takes place and enzyme activity decreases due to dramatic decrease in intact cells. On the other hand, below this critical level, the opposite scenario occurs and enzyme activity increases. In the present study, ROS concentration might have been restricted in a level around above-mentioned critical level so that opposite mechanisms had balanced each other and no alteration was seen.

Overall, the only noteworthy effect extracted from the present results with respect to Legalon® SIL is the antioxidant effect of this compound. The proposed mechanisms for the antioxidant effect of silymarin/silibinin derived from studies conducted in tissues other than skeletal muscle are as follows: (i) scavenging ROS, (ii) increasing the content of glutathione, (iii) stimulation of the expression of SOD, (iv) prevention of the effects of tumour necrosis factor-α (TNF-α), which markedly increases lipid peroxidation, (v) inhibition of neutrophil migration, and (vi) inhibition of CYP450, some of which generate ROS\(^{20}\). In one study, silymarin has been shown to reduce the levels of TNF-α in parallel with those of heat shock protein (HSP)-70, SOD, and thiobarbituric acid-reactive substance (TBARS) in a rat model of mesenteric IRI model, indicating the role of TNF-α in the
antioxidant effect of silymarin\(^{17}\). Similarly, silymarin prescribed to patients undergoing coronary artery bypass grafting surgery decreased both TNF-\(\alpha\) and MDA levels in comparison with control patients\(^{30}\). Further investigations are needed to determine with certainty which of these mechanisms are responsible for IRI in rat skeletal muscle.

**Conclusions**

Therapeutic effect of Legalon\(^{®}\) SIL was shown to be limited due to its inefficiency on tissue viability, it may be utilized as an adjuvant therapy rather than used solely. The advantage of Legalon\(^{®}\) SIL over other antioxidant substances is that it is currently used in several countries for the treatment of mushroom poisoning and may enable Legalon\(^{®}\) SIL to, more rapidly, become available for any new indication. However, further studies are needed to prove the efficacy of Legalon\(^{®}\) SIL in the skeletal muscle IRI in combination with other beneficial substances.

**References**


Acknowledgement

To Madaus GmbH, Cologne, Germany (Rottapharm/Madaus Group) for sending us Legalon® SIL as a gift.

Correspondence:
Yusuf Ergün
Department of Pharmacology, School of Medicine
Kahramanmaraş Sütçü İmam University
46100, Kahramanmaraş, Turkey
Phone: +90 344 2803357
Phax: +90 344 2803409
yusuf ergun@yahoo.com; yusuf ergun@ksu.edu.tr

Received: Dec 15, 2015
Review: Feb 18, 2016
Accepted: Mar 12, 2016
Conflict of interest: none
Financial source: Scientific Research Projects, Kahramanmaraş Sütçü İmam University

1Research performed at Departments of Pharmacology and Biochemistry, School of Medicine, Kahramanmaraş Sütçü İmam University, Turkey.